Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 56 clinical trials
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered according to different dosing schedules as a single agent and in combination with dexamethasone.

lenalidomide
t-cell lymphoma
refractory non-hodgkin's lymphoma
b-cell lymphoma
antibody therapy
  • 0 views
  • 01 May, 2022
  • 11 locations
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

This is a phase I clinical study to evaluate the safety and efficacy of CAR-T infusion preparation in the treatment of CD19-positive relapsed/refractory non-Hodgkin lymphoma.

mantle cell lymphoma
diffuse large b-cell lymphoma
chronic lymphocytic leukemia
cell transplantation
refractory non-hodgkin's lymphoma
  • 0 views
  • 05 Jul, 2022
  • 1 location
A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

This study is a multicenter, non randomized, single arm, open clinical trial. The selected disease was relapsed / refractory NHL, and the disease was classified into highly aggressive lymphoma

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-96673 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non-Hodgkin's Lymphoma (R/R NHL). The study will

refractory non-hodgkin's lymphoma
  • 0 views
  • 25 Oct, 2022
  • 9 locations
Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients With Residual, Relapsed or Refractory Non-Hodgkin Lymphoma or Histiocytic/Dendritic Cell Neoplasm

This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with non-Hodgkin lymphoma or histiocytic/dendritic cell neoplasm that has cancer cells remaining after attempts to remove the cancer have been made (residual), has come back …

  • 0 views
  • 23 Apr, 2022
  • 1 location
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or stage IV breast cancer that has returned after a period of improvement or does not respond to treatment. …

metastatic disease
hodgkin's disease
t-cell lymphoma
platelet count
cancer
  • 14 views
  • 22 Mar, 2022
  • 1 location
Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

This is a Multicenter, Open-Label, Phase Ib/II Study of ADG106 in Combination with PD-1 Antibody in Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. The primary

refractory non-hodgkin's lymphoma
solid tumor
  • 0 views
  • 22 Mar, 2022
  • 1 location
A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19/22 CART cells combined with PD-1 Inhibitor in relapsed/refractory B Cell Lymphoma.

  • 0 views
  • 12 Aug, 2021
  • 1 location
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

This phase I/II trial aims to evaluate safety and efficacy of Chidamide, Decitabine and Immune checkpoint inhibitors in relapsed/refractory Non-Hodgkin Lymphoma and advanced solid tumors.

  • 0 views
  • 20 Apr, 2022
  • 1 location
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects (NHL)

Non-Hodgkin Lymphoma (NHL)

non-hodgkin's lymphoma refractory
diffuse large b-cell lymphoma
measurable disease
hodgkin's disease
refractory non-hodgkin's lymphoma
  • 0 views
  • 25 Jan, 2022
  • 2 locations